Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextenza with LipiFlow for MGD and Dry Eye
NCT04413279Phase 4Completed
- Sponsor
- Eye Surgeons of Indiana
- Start
- Aug 2020
- Primary completion
- Jul 2021
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ozurdex in meibomian gland dysfunction (MGD), dry eye syndrome (DED), sponsored by Eye Surgeons of Indiana. Started Aug 2020; status: completed.
02
Drugs
ozurdex
03
Conditions
meibomian gland dysfunction (MGD)dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT04413279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04413279.